3D Medicines Acquires China Rights to Two Immunotherapies in $202 Million Deal

3D Medicines of Shanghai acquired greater China rights to two Sellas cancer immunotherapies in an agreement worth up to $202 million. 3DMed will develop and commercialize Sellas' late-stage candidate, galinpepimut-S (GPS), and its next-gen heptavalent immunotherapy, GPS+, currently in preclinical stage. The $202 million includes a $7.5 upfront payment and a $8 million near-term milestone. 3DMed will also pay royalties on sales. Sellas is headquartered in New York City; it acquired rights to GPS from Memorial Sloan Kettering Cancer Center. More details.... Share this with colleagues: // //